Huons Accelerates Phase 2 Trials of Dry Eye Drug 'HUC1-394'...First Patient Enrolled
Huons is set to accelerate Phase 2 clinical trials for its peptide-based dry eye disease drug candidate, 'HUC1-394'.
Huons announced on July 3 that it has successfully completed the enrollment of the first patient for the Phase 2 clinical trial of 'HUC1-394'.
After obtaining approval for the Phase 2 clinical trial plan (IND) for HUC1-394 in March, Huons carried out the patient screening process and completed the First Patient In (FPI) as of today. The company plans to begin full-scale collection of clinical data moving forward.
This Phase 2 clinical trial will be conducted at leading medical institutions in Korea, including Severance Hospital at Yonsei University College of Medicine, targeting 150 patients with dry eye disease. Using a multi-center, randomized, double-masked (RCT) design, the trial will evaluate the safety and efficacy of HUC1-394.
Huons aims to reach the Last Patient Last Visit (LPLV) by the second half of next year and plans to announce the Clinical Study Report (CSR) thereafter. If efficacy and safety data are secured in Phase 2, preparations for Phase 3 clinical trials will begin.
Kyungmi Park, Executive Vice President and Head of R&D at Huons, stated, "With the enrollment of the first patient in Phase 2, we will work closely with our research team to accelerate development," adding, "We will do our utmost to provide innovative treatment options for patients with dry eye disease."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, HUC1-394 is a peptide-based eye drop introduced by Huons from Novacell Technology Inc. It works by activating the formyl peptide receptor 2 (FPR2), which is involved in the resolution of inflammation in the body. By not only suppressing inflammation but also bringing inflammatory responses to a normal resolution and repairing damaged tissues, HUC1-394 is expected to provide a fundamental therapeutic effect for dry eye disease as a novel drug candidate.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.